In this episode of "Better Biopharma," host Tyler Menichiello is joined by Bonum Therapeutics' chief scientific officer, Diane Hollenbaugh, Ph.D., and chief business officer, Neela Patel, Ph.D. They talk about the inherent challenges of developing complex molecules like conditionally active biologics, sharing advice on CMC strategy, analytical methodology, and working with contract manufacturing and development partners. Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenic...
All content for Better Biopharma is the property of Tyler Menichiello and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode of "Better Biopharma," host Tyler Menichiello is joined by Bonum Therapeutics' chief scientific officer, Diane Hollenbaugh, Ph.D., and chief business officer, Neela Patel, Ph.D. They talk about the inherent challenges of developing complex molecules like conditionally active biologics, sharing advice on CMC strategy, analytical methodology, and working with contract manufacturing and development partners. Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenic...
Developing Antibodies To Block Neuroinflammation With MindImmune's Stevin Zorn, Ph.D.
Better Biopharma
44 minutes
2 weeks ago
Developing Antibodies To Block Neuroinflammation With MindImmune's Stevin Zorn, Ph.D.
In this episode of "Better Biopharma," host Tyler Menichiello is joined by MindImmune's president and CEO, Stevin Zorn, Ph.D. They discuss the development of the company's lead candidate, MITI-101, a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation linked to Alzheimer's disease. Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/ Keep up with everything biomanufacturing at Bioprocess Online: http...
Better Biopharma
In this episode of "Better Biopharma," host Tyler Menichiello is joined by Bonum Therapeutics' chief scientific officer, Diane Hollenbaugh, Ph.D., and chief business officer, Neela Patel, Ph.D. They talk about the inherent challenges of developing complex molecules like conditionally active biologics, sharing advice on CMC strategy, analytical methodology, and working with contract manufacturing and development partners. Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenic...
